Quick Answer
FATE THERAPEUTICS INC reported Total Revenue of $6.65 million for fiscal year 2025.
FATE THERAPEUTICS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $6.65M -51.2% |
$13.63M -78.5% |
$63.53M -34.0% |
$96.30M +72.4% |
$55.85M +77.7% |
$31.43M +194.3% |
| Revenue (ASC 606) | $6.65M -51.2% |
$13.63M -78.5% |
$63.53M -34.0% |
$96.30M +72.4% |
$55.85M +77.7% |
$31.43M +194.3% |
| Net Income | -$136.31M +26.8% |
-$186.26M -15.7% |
-$160.93M +42.9% |
-$281.72M -32.8% |
-$212.15M -22.4% |
-$173.39M -76.7% |
| Diluted EPS | -$1.15 +29.9% |
-$1.64 +0.0% |
-$1.64 +43.6% |
-$2.91 -29.9% |
-$2.24 -6.7% |
-$2.10 |
| Total Assets | $318.94M -27.6% |
$440.69M -12.9% |
$506.22M -28.3% |
$705.56M -23.4% |
$921.46M +48.0% |
$622.46M +105.9% |
| Cash and Equivalents | $46.63M +29.3% |
$36.06M -13.9% |
$41.87M -31.7% |
$61.33M -54.1% |
$133.58M -20.2% |
$167.35M +67.7% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $207.18M -35.0% |
$318.73M -13.5% |
$368.42M -23.9% |
$483.94M -28.7% |
$678.84M +76.6% |
$384.44M +57.1% |
| R&D Expense | $107.83M -20.1% |
$135.00M -21.8% |
$172.60M -46.1% |
$320.45M +48.7% |
$215.52M +71.6% |
$125.62M +43.1% |
| Operating Income | -$147.70M +29.8% |
-$210.28M -10.4% |
-$190.51M +38.2% |
-$308.39M -42.1% |
-$216.99M -69.4% |
-$128.09M -27.2% |
| Shares Outstanding | 115.36M +1.3% |
113.93M +15.5% |
98.63M +1.4% |
97.29M +1.6% |
95.73M +9.1% |
87.72M +15.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.74M | -43.4% | -8.7% |
| Revenue (ASC 606) | September 30, 2025 | $1.74M | -43.4% | -8.7% |
| Net Income | September 30, 2025 | -$32.25M | +32.4% | +5.3% |
| Diluted EPS | September 30, 2025 | -$0.27 | +32.5% | +6.9% |
| Total Assets | September 30, 2025 | $343.67M | -30.6% | -7.5% |
| Cash and Equivalents | September 30, 2025 | $40.62M | +7.2% | -1.5% |
| Long-Term Debt | June 30, 2019 | $9.47M | -26.2% | -13.6% |
| Stockholders Equity | September 30, 2025 | $234.07M | -35.4% | -10.4% |
| R&D Expense | September 30, 2025 | $25.84M | -25.4% | -5.8% |
| Operating Income | September 30, 2025 | -$34.73M | +33.7% | +6.0% |
| Shares Outstanding | September 30, 2025 | 115.34M | +1.3% | +0.6% |
- FATE THERAPEUTICS INC reported Total Revenue of $6.65 million for fiscal year 2025.
- FATE THERAPEUTICS INC showed a decrease of -51.2% in Total Revenue compared to the prior fiscal year.
- FATE THERAPEUTICS INC reported Revenue (ASC 606) of $6.65 million for fiscal year 2025.
- FATE THERAPEUTICS INC showed a decrease of -51.2% in Revenue (ASC 606) compared to the prior fiscal year.
- FATE THERAPEUTICS INC reported Net Income of -$136.31 million for fiscal year 2025.
- FATE THERAPEUTICS INC showed an increase of +26.8% in Net Income compared to the prior fiscal year.
- FATE THERAPEUTICS INC reported Diluted EPS of $1.15 per share (loss) for fiscal year 2025.
- FATE THERAPEUTICS INC showed an increase of +29.9% in Diluted EPS compared to the prior fiscal year.
- FATE THERAPEUTICS INC reported Total Assets of $318.94 million for fiscal year 2025.
- FATE THERAPEUTICS INC showed a decrease of -27.6% in Total Assets compared to the prior fiscal year.
- FATE THERAPEUTICS INC reported Cash and Equivalents of $46.63 million for fiscal year 2025.
- FATE THERAPEUTICS INC showed an increase of +29.3% in Cash and Equivalents compared to the prior fiscal year.
- FATE THERAPEUTICS INC reported Long-Term Debt of $12.45 million for fiscal year 2018.
- FATE THERAPEUTICS INC showed a decrease of -16.0% in Long-Term Debt compared to the prior fiscal year.
- FATE THERAPEUTICS INC reported Stockholders Equity of $207.18 million for fiscal year 2025.
- FATE THERAPEUTICS INC showed a decrease of -35.0% in Stockholders Equity compared to the prior fiscal year.
- FATE THERAPEUTICS INC reported R&D Expense of $107.83 million for fiscal year 2025.
- FATE THERAPEUTICS INC showed a decrease of -20.1% in R&D Expense compared to the prior fiscal year.
- FATE THERAPEUTICS INC reported Operating Income of -$147.70 million for fiscal year 2025.
- FATE THERAPEUTICS INC showed an increase of +29.8% in Operating Income compared to the prior fiscal year.
- FATE THERAPEUTICS INC reported Shares Outstanding of 115.36 million shares for fiscal year 2025.
- FATE THERAPEUTICS INC showed an increase of +1.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: